2017-10-24T08:25:10
NEW DRUG TREATMENT FOR HIV INFECTED PATIENTS
Study suggests four in one tablet as switch option for treatment of HIV-1 infection in adults
Findings of the EMERALD phase 3 noninferiority trial published online October 6, 2017 in The Lancet HIV have demonstrated that a new single-tablet regimen (STR) containing darunavir, cobicistat, emtricitabine and tenofovir alafenamide maintained viral suppression at 48 weeks of the study in most study participants with HIV-1.